John Alam

6.8k total citations · 2 hit papers
37 papers, 2.8k citations indexed

About

John Alam is a scholar working on Physiology, Hepatology and Pharmacology. According to data from OpenAlex, John Alam has authored 37 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 11 papers in Hepatology and 9 papers in Pharmacology. Recurrent topics in John Alam's work include Hepatitis C virus research (11 papers), Alzheimer's disease research and treatments (10 papers) and Cholinesterase and Neurodegenerative Diseases (9 papers). John Alam is often cited by papers focused on Hepatitis C virus research (11 papers), Alzheimer's disease research and treatments (10 papers) and Cholinesterase and Neurodegenerative Diseases (9 papers). John Alam collaborates with scholars based in United States, Netherlands and France. John Alam's co-authors include Lindsay McNair, Robert S. Kauffman, John G. McHutchison, Stuart C. Gordon, Ira M. Jacobson, Andrew J. Muir, Gregory T. Everson, Mark Sulkowski, Nicole Forestier and Stefan Zeuzem and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and PLoS ONE.

In The Last Decade

John Alam

34 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

2009 803 citations John G. McHutchison, Gregory T. Everson et al. New England Journal of Medicine profile →
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

2009 771 citations Christophe Hézode, Nicole Forestier et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John Alam United States	19	1.9k	1.6k	540	364	323	37	2.8k
François H.T. Duong Switzerland	23	1.5k 0.8×	1.2k 0.8×	119 0.2×	448 1.2×	423 1.3×	36	2.4k
Pascal Lapierre Canada	24	1.0k 0.5×	856 0.5×	112 0.2×	239 0.7×	325 1.0×	47	1.8k
Young–Hwa Chung South Korea	30	1.7k 0.9×	1.7k 1.1×	84 0.2×	29 0.1×	745 2.3×	85	3.1k
Jens Kort United States	17	905 0.5×	717 0.4×	407 0.8×	108 0.3×	129 0.4×	61	1.4k
Moritoshi Kinoshita Japan	28	341 0.2×	498 0.3×	121 0.2×	99 0.3×	1.0k 3.1×	75	2.3k
Karim Abid Switzerland	15	1.1k 0.6×	1.1k 0.6×	72 0.1×	98 0.3×	537 1.7×	35	1.8k
John Vergalla United States	24	928 0.5×	774 0.5×	76 0.1×	97 0.3×	355 1.1×	39	1.9k
Kerstin Herzer Germany	19	776 0.4×	924 0.6×	83 0.2×	34 0.1×	484 1.5×	76	1.8k
Toshihiro Higashi Japan	26	466 0.2×	423 0.3×	72 0.1×	55 0.2×	670 2.1×	88	1.8k
Milton G. Mutchnick United States	20	645 0.3×	703 0.4×	85 0.2×	41 0.1×	180 0.6×	78	1.4k

Countries citing papers authored by John Alam

Since Specialization

Citations

This map shows the geographic impact of John Alam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Alam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Alam more than expected).

Fields of papers citing papers by John Alam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Alam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Alam. The network helps show where John Alam may publish in the future.

Co-authorship network of co-authors of John Alam

This figure shows the co-authorship network connecting the top 25 collaborators of John Alam. A scholar is included among the top collaborators of John Alam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Alam. John Alam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alam, John & Marwan N. Sabbagh. (2025). Perspective: Minimally clinically important “symptomatic” benefit associated with disease modification resulting from anti‐amyloid immunotherapy. Alzheimer s & Dementia Translational Research & Clinical Interventions. 11(1). e70035–e70035. 1 indexed citations

Alam, John, et al.. (2024). Neflamapimod treatment reduces plasma glial fibriallary acidic protein levels in patients with pure dementia with Lewy bodies (DLB). Alzheimer s & Dementia. 20(S6).

Alam, John & Ralph A. Nixon. (2023). Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come. Molecular Neurodegeneration. 18(1). 74–74. 5 indexed citations

Alam, John, Paul Maruff, Susan R. Doctrow, et al.. (2023). Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies. Neurology. 101(17). e1708–e1717. 16 indexed citations

Alam, John & Ralph A. Nixon. (2021). Disease-modifying pharmacological approaches to correcting basal forebrain cholinergic neuronal (BFCN) dysfunction and degeneration. Neuropsychopharmacology. 47(1). 405–406. 1 indexed citations

Alam, John, et al.. (2020). Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level. PLoS ONE. 15(12). e0233073–e0233073. 7 indexed citations

Alam, John. (2015). Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats. Journal of Alzheimer s Disease. 48(1). 219–227. 67 indexed citations

Rustgi, Vinod K., William M. Lee, Eric Lawitz, et al.. (2009). Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders†‡. Hepatology. 50(6). 1719–1726. 18 indexed citations

Hézode, Christophe, Nicole Forestier, Geoffrey Dusheiko, et al.. (2009). Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection. New England Journal of Medicine. 360(18). 1839–1850. 771 indexed citations breakdown →

10.

McHutchison, John G., Gregory T. Everson, Stuart C. Gordon, et al.. (2009). Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection. New England Journal of Medicine. 360(18). 1827–1838. 803 indexed citations breakdown →

11.

Hézode, Christophe, Péter Ferenci, Geoffrey Dusheiko, et al.. (2008). 160 Prove2 Study: Treatment of Chronic Hepatitis C with Telaprevir (TVR)in Combination with Peginterferon-Alfa-2a with or Without Ribavirin, Interim Analysis Results. Gastroenterology. 134(4). A–755. 4 indexed citations

12.

Marcellin, Patrick, Yves Horsmans, Frederik Nevens, et al.. (2007). Phase 2 study of the combination of merimepodib with peginterferon-α2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. Journal of Hepatology. 47(4). 476–483. 20 indexed citations

13.

Alam, John. (2003). Apoptosis: target for novel drugs. Trends in biotechnology. 21(11). 479–483. 35 indexed citations

14.

Habersetzer, François, Nathalie Boyer, Patrick Marcellin, et al.. (2000). A pilot study of recombinant interferon beta‐1a for the treatment of chronic hepatitis C. Liver International. 20(6). 437–441. 16 indexed citations

15.

Rogge, Mark, et al.. (1998). Impaired Bioavailability of Interferon Beta-1a when Administered Intramuscularly by Needle-Free Injection. Drug Delivery. 5(4). 275–280. 3 indexed citations

16.

Alam, John, Susan Goelz, Patrice Rioux, et al.. (1997). Comparative Pharmacokinetics and Pharmacodynamics of Two Recomhinant Human Interferon Beta-la (IFNβ-la) Products Administered Intramuscularly in Healthy Male and Female Volunteers. Pharmaceutical Research. 14(4). 546–549. 50 indexed citations

17.

Rudick, Richard A., Richard M. Ransohoff, Richard D. Peppler, et al.. (1996). Interferon beta induces interleukin‐10 expression: Relevance to multiple sclerosis. Annals of Neurology. 40(4). 618–627. 202 indexed citations

18.

Schacker, Timothy W., Ann C. Collier, Robert W. Coombs, et al.. (1995). Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection.. PubMed. 9(2). 145–52. 25 indexed citations

19.

Alam, John. (1995). Interferon-β treatment of human disease. Current Opinion in Biotechnology. 6(6). 688–691. 18 indexed citations

20.

Schacker, Timothy W., Robert W. Coombs, Ann C. Collier, et al.. (1994). The Effects of High-Dose Recombinant Soluble CD4 on Human Immunodeficiency Virus Type 1 Viremia. The Journal of Infectious Diseases. 169(1). 37–40. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact